462 related articles for article (PubMed ID: 38449875)
21. Functional Diversities of Regulatory T Cells in the Context of Cancer Immunotherapy.
Gao R; Shi GP; Wang J
Front Immunol; 2022; 13():833667. PubMed ID: 35371055
[TBL] [Abstract][Full Text] [Related]
22. Tumor resident regulatory T cells.
Glasner A; Plitas G
Semin Immunol; 2021 Feb; 52():101476. PubMed ID: 33906820
[TBL] [Abstract][Full Text] [Related]
23. Targeting regulatory T cells in tumors.
Liu C; Workman CJ; Vignali DA
FEBS J; 2016 Jul; 283(14):2731-48. PubMed ID: 26787424
[TBL] [Abstract][Full Text] [Related]
24. Roles of regulatory T cells in cancer immunity.
Takeuchi Y; Nishikawa H
Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
[TBL] [Abstract][Full Text] [Related]
25. FOXP3 (in)stability and cancer immunotherapy.
Mortezaee K
Cytokine; 2024 Jun; 178():156589. PubMed ID: 38547750
[TBL] [Abstract][Full Text] [Related]
26. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
27. The Role of Regulatory T Cells in Cancer Treatment Resistance.
Dąbrowska A; Grubba M; Balihodzic A; Szot O; Sobocki BK; Perdyan A
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762416
[TBL] [Abstract][Full Text] [Related]
28. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy.
Tay C; Tanaka A; Sakaguchi S
Cancer Cell; 2023 Mar; 41(3):450-465. PubMed ID: 36917950
[TBL] [Abstract][Full Text] [Related]
29. Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity.
Kalim KW; Yang JQ; Wunderlich M; Modur V; Nguyen P; Li Y; Wen T; Davis AK; Verma R; Lu QR; Jegga AG; Zheng Y; Guo F
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36427906
[TBL] [Abstract][Full Text] [Related]
30. Significance of regulatory T cells in cancer immunology and immunotherapy.
Sugiyama D; Hinohara K; Nishikawa H
Exp Dermatol; 2023 Mar; 32(3):256-263. PubMed ID: 36458459
[TBL] [Abstract][Full Text] [Related]
31. Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody.
Weaver JD; Stack EC; Buggé JA; Hu C; McGrath L; Mueller A; Wong M; Klebanov B; Rahman T; Kaufman R; Fregeau C; Spaulding V; Priess M; Legendre K; Jaffe S; Upadhyay D; Singh A; Xu CA; Krukenberg K; Zhang Y; Ezzyat Y; Saddier Axe D; Kuhne MR; Meehl MA; Shaffer DR; Weist BM; Wiederschain D; Depis F; Gostissa M
Oncoimmunology; 2022; 11(1):2141007. PubMed ID: 36352891
[TBL] [Abstract][Full Text] [Related]
32. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
33. Regulation of Treg Cell Metabolism and Function in Non-Lymphoid Tissues.
Yang K
Front Immunol; 2022; 13():909705. PubMed ID: 35720275
[TBL] [Abstract][Full Text] [Related]
34. The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies.
González-Navajas JM; Fan DD; Yang S; Yang FM; Lozano-Ruiz B; Shen L; Lee J
Front Immunol; 2021; 12():625783. PubMed ID: 33717139
[TBL] [Abstract][Full Text] [Related]
35. FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity.
Whiteside TL
Expert Opin Ther Targets; 2018 Apr; 22(4):353-363. PubMed ID: 29532697
[TBL] [Abstract][Full Text] [Related]
36. Immunometabolic Checkpoints of Treg Dynamics: Adaptation to Microenvironmental Opportunities and Challenges.
Pacella I; Piconese S
Front Immunol; 2019; 10():1889. PubMed ID: 31507585
[TBL] [Abstract][Full Text] [Related]
37. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
38. Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy.
Kim JH; Kim BS; Lee SK
Immune Netw; 2020 Feb; 20(1):e4. PubMed ID: 32158592
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic targeting of regulatory T cells in cancer.
Shan F; Somasundaram A; Bruno TC; Workman CJ; Vignali DAA
Trends Cancer; 2022 Nov; 8(11):944-961. PubMed ID: 35853825
[TBL] [Abstract][Full Text] [Related]
40. Factors regulating apoptosis and homeostasis of CD4+ CD25(high) FOXP3+ regulatory T cells are new therapeutic targets.
Yang XF
Front Biosci; 2008 Jan; 13():1472-99. PubMed ID: 17981643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
